New Study Shows Meganuclease-Driven Targeted Integration Using Cellectis bioresearch’s cGPS® CHO-K1 kit to be highly efficient f

Paris, July 19, 2010 - Cellectis bioresearch, the specialist in genome customizationand a subsidiary of Cellectis (Alternext: ALCLS), today announced the publication ofa scientific study describing a novel method,

based on meganuclease-driventargeted integration, for the generation of stable cell lines compatible with highthroughput screening (HTS)1. The study demonstrated Cellectis bioresearch’stechnology to be faster, more reliable and efficient in deriving cell-based assays forHTS studies than classical methods. The study has been published online byJournal of Biomolecular Screening

target="_blank">jbx.sagepub.com/cgi/content/abstract/1087057110375115v1

.

target="_blank">http://jbx.sagepub.com/cgi/content/abstract/1087057110375115v1.

The development of cell-based assays for HTS approaches is important to screenmolecules on pharmaceutical targets and often requires the generation of stable celllines. However, these cell lines are essentially created by random integration of agene of interest (GOI) with no control over the level and stability of gene expression.In this study, scientists from the Servier Research institute used Cellectisbioresearch’s cellular Genome Positioning System, or cGPS®, in CHO-K1 cells, toaccomplish targeted integration of different GOIs. Five different GOIs representing 3major drug target classes were stably integrated at the same locus in cGPS® CHOK1cells. Characterization of the targeted clones revealed that the cGPS® CHO-K1system was more rapid (2-week protocol), efficient (all selected clones expressedthe GOI), reproducible (GOI expression level variation of 12% maximum), andstable over time (no change in GOI expression after 23 weeks of culture) thanclassical random integration.

“Achieving a physiological level of expression compatible with the relevantfunctional assay is important in testing pharmaceutical targets”, explained JeanBoutin, Director of the Molecular and Cellular Pharmacology Division of theSERVIER Research Institute. “We found that proteins expressed in the cGPS®CHO-K1 cells are biologically active and have enzymatic constants, localization andfunction close to the published values of their wild-type endogenous counterparts.This fast and robust method opens the door for creating large collections of celllines expressing therapeutically relevant GOIs, enhancing the productivity of HTS”.

News Source : New Study Shows Meganuclease-Driven Targeted Integration Using Cellectis bioresearch’s cGPS® CHO-K1 kit to be highly efficient for drug discovery.